Johnson & Johnson reported Q2 2026 adjusted EPS of $2.90, above the $2.85 estimate, and raised its full-year adjusted EPS and sales guidance.
LiveSquawk07/15, 05:27 PM
- Adj EPS $2.90 (est $2.85)
- Sales $25.31B (est 25.04B)
- Medtech Sales $8.93b (est $8.99b)
- Medicine Revenue $16.38b (est $16.12b)
Figures as quoted by LiveSquawk